MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.45
-0.02
-0.37%
After Hours: 5.47 +0.02 +0.37% 19:48 04/09 EDT
OPEN
5.54
PREV CLOSE
5.47
HIGH
5.84
LOW
5.33
VOLUME
4.19M
TURNOVER
--
52 WEEK HIGH
6.16
52 WEEK LOW
0.4426
MARKET CAP
399.21M
P/E (TTM)
-12.5808
1D
5D
1M
3M
1Y
5Y
Do Options Traders Know Something About Seelos (SEEL) Stock We Don't?
Zacks · 2d ago
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 3d ago
Seelos Therapeutics shares 6% higher as BTIG reiterates buy following Aptar deal
BTIG analyst Bert Hazlett is reiterating his buy recommendation and $14 price target for shares of Seelos Therapeutics (SEEL) following yesterday's device partnership with Aptar Pharma (ATR).That deal calls for
Seekingalpha · 3d ago
Thinking about buying stock in Hyliion Holdings, BlackBerry, GT Biopharma, Seelos Therapeutics, or Oncternal Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYLN, BB, GTBP, SEEL, and ONCT.
PR Newswire - PRF · 4d ago
Thinking about buying stock in Phunware, Broadwind, Seelos Therapeutics, Golden Nugget Online Gaming, or Heron Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, BWEN, SEEL, GNOG, and HRTX.
PR Newswire - PRF · 5d ago
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the signing of an agreement between Seelos and AptarG...
PR Newswire · 5d ago
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the signing of an agreement between Seelos and AptarG...
PR Newswire · 5d ago
Seelos partners with AptarGroup for drug delivery system
Seelos Therapeutics, (SEEL) has partnered with AptarGroup for the co-exclusive use and supply of Aptar Pharma's Bidose ("BDS") Liquid System device for Seelos’s intranasal candidate SLS-002.The agreement covers SLS-002’s studies
Seekingalpha · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SEEL stock price target is 11.75 with a high estimate of 15.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 7.74M
% Owned: 10.56%
Shares Outstanding: 73.25M
TypeInstitutionsShares
Increased
9
2.71M
New
9
649.42K
Decreased
5
199.50K
Sold Out
10
650.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Raj Mehra
Chief Scientific Officer
Warren Wasiewski
Director
Judith Dunn
Director
Brian Lian
Director
Daniel O'Connor
Director
Richard Pascoe
Independent Director
Wendell Wierenga
No Data
  • All
  • Financials
  • Insiders
More
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.